Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Seres Therapeutics, Inc.

Market Cap 55.2M 47.67M 43.93M 41.12M 77.07M 5.25B 78.26M 519M 202M 2.55B 207M 203M 8.84B P/E Ratio 2026 *
-0.62x
P/E Ratio 2027 * -0.55x
Enterprise Value 55.2M 47.67M 43.93M 41.12M 77.07M 5.25B 78.26M 519M 202M 2.55B 207M 203M 8.84B EV / Sales 2026 *
76,664x
EV / Sales 2027 * 76,664x
Free-Float
88.22%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Seres Therapeutics, Inc.

1 day-9.81%
1 week-14.03%
Current month-22.13%
1 month-26.55%
3 months-33.95%
6 months-66.35%
Current year-61.69%
1 week 5.63
Extreme 5.63
6.99
1 month 5.63
Extreme 5.63
8.1
Current year 5.63
Extreme 5.63
16.42
1 year 5.63
Extreme 5.63
29.98
3 years 5.63
Extreme 5.63
122.08
5 years 5.63
Extreme 5.63
501.1
10 years 5.63
Extreme 5.63
770
Manager TitleAgeSince
Chief Executive Officer 70 2026-03-01
Chief Executive Officer 58 2025-07-31
President 51 2026-03-01
Director TitleAgeSince
Chairman 70 2026-03-01
Director/Board Member 50 2019-01-14
Director/Board Member 80 2015-03-31
Date Insider Type Main position Quantity % Market Cap.
05-17Sell

General Counsel

-79 0.0008%
05-17Sell

Chairperson

-77 0.0008%
05-17Sell

Chief Operating Officer

-59 0.0006%
Change 5-day change 1-year change 3-year change Capi.($)
-9.81%-14.03%-24.00%-95.40% 55.2M
+1.03%+2.30%+55.91%+114.22% 56.42B
+2.72%+3.26%+46.05%+44.91% 44.54B
+1.12%+2.79%-15.04%-21.68% 22.9B
+1.17%+3.85%-0.89%+403.86% 21.21B
+3.81%-5.07%+11.00%-30.62% 16.4B
+0.15%+2.24%+9.32%-39.30% 15.4B
-0.69%+0.82%+27.75%+176.72% 13.35B
+5.27%+5.54%+19.65% - 12.36B
+1.61%+1.28%+95.75%+205.26% 11.15B
Average +0.64%+1.11%+22.55%+84.22% 21.38B
Weighted average by Cap. +1.72%+2.36%+32.02%+99.54%

Financials

2026 *2027 *
Net sales 720 621.86 573.05 536.4 1.01K 68.44K 1.02K 6.77K 2.64K 33.31K 2.7K 2.64K 115K 720 621.86 573.05 536.4 1.01K 68.44K 1.02K 6.77K 2.64K 33.31K 2.7K 2.64K 115K
Net income -81.44M -70.34M -64.81M -60.67M -114M -7.74B -115M -765M -298M -3.77B -306M -299M -13.05B -91.95M -79.41M -73.18M -68.5M -128M -8.74B -130M -864M -337M -4.25B -345M -338M -14.73B
Net Debt - -
Logo Seres Therapeutics, Inc.
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.
Employees
66
Date Price Change Volume
26-06-12 5.700 $ -9.81% 109,371
26-06-11 6.320 $ -2.62% 85,263
26-06-10 6.490 $ +2.53% 72,610
26-06-09 6.330 $ +0.80% 83,563
26-06-08 6.280 $ -5.28% 88,994
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
5.700USD
Average target price
22.00USD
Spread / Average Target
+285.96%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MCRB Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!